Quantcast

Astute Medical To Host Acute Kidney Injury Symposium At CRRT 2014

March 3, 2014

Symposium Highlights New Biomarkers for AKI Risk Assessment

SAN DIEGO, March 3, 2014 /PRNewswire/ — Leading critical care experts will discuss biomarkers for risk assessment of acute kidney injury (AKI) at an educational symposium to be held at the19(th) International Conference on Advances In Critical Care – CRRT 2014 in San Diego. The symposium, “New AKI Biomarkers: A Revolution in Risk Assessment,” will be held on Thursday, March 6, 2014, from 12:40 p.m. to 2:00 p.m. local time and is sponsored by Astute Medical, Inc.

Conference attendees can register for the symposium at AKIAssessment.com. Event participants and others can follow the live event via Twitter @ACuteKidneyMan.

Globally, AKI is emerging as a significant public hazard given its link to increased mortality and morbidity, longer lCU stays, and higher in-hospital cost. Its incidence (2.1/1000 population) is similar to that of acute myocardial infarction, or heart attack.

A study recently published in the Clinical Journal of the American Society of Nephrology suggested that AKI could be more deadly than heart attack. Unlike heart attack, AKI is asymptomatic lacking warning signs such as pain, shortness of breath or other clinical symptoms, particularly in the early stages when intervention is most beneficial.

Symposium presenters will discuss research pertaining to biomarkers that have been discovered to be useful in the assessment of AKI risk. Program highlights include:

    --  Dr. Lakhmir Chawla of the George Washington Medical Faculty, who will
        chair and moderate the symposium. Dr. Chawla led a recently published
        study suggesting that AKI may be more deadly than heart attack;
    --  Dr. John Kellum of the University of Pittsburgh, who will discuss the
        latest findings of cell cycle arrest biomarkers;
    --  Dr. Andrew Shaw, who will present the implications for management of
        AKI;
    --  Dr. Alex Zarbock of the University of Munster, who will present
        practical cases of acute kidney injury.

Astute Medical, Inc., has developed the CE-marked NephroCheck(® )Test to aid in the early assessment of moderate or severe AKI risk in the critically ill. The NephroCheck(®) Test and the Astute140(®) Meter are sold in Europe. The NephroCheck(®) Test and the Astute140(®) Meter are not available in the United States.

The test utilizes fluorescence immunoassay technology to detect and measure two biomarkers of AKI, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. The release of TIMP-2 and IGFBP-7 by kidney cells acts as a biological alarm signaling that the cells are acutely stressed and the kidney is at risk for AKI, which can cause permanent damage and loss of function.

The recently published Kidney Disease Improving Global Outcomes (KDIGO) Guideline for AKI recommends prompt evaluation of patients along with the implementation of kidney-sparing interventions for patients determined to be at risk and thus vulnerable to permanent damage from unchecked AKI.

CRRT is one of the leading and most influential international conferences in the rapidly developing field of critical care nephrology and continuous renal replacement therapy. Additional information can be found at crrtonline.com/conference/.

Not attending the CRRT? For more information stay connected with Astute Medical at AstuteMedical.com or via:

    --  @ACuteKidneyMan on Twitter
    --  Astute Medical on YouTube

About Astute Medical, Inc.

Named by the Wall Street Journal as one of the Top 10 Healthcare Start-Ups of 2012, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company’s focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical’s current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For additional information, please visit AstuteMedical.com.

Astute Medical(®), the AM logo, Astute140(®), NephroCheck(®) and the NephroCheck(®) logo are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectual-property. PN 0280 Rev A 2014/02/25

SOURCE Astute Medical, Inc.


Source: PR Newswire



comments powered by Disqus